

**PUSAT PAKAR MATA**

**TOPVISION<sup>®</sup>**

**EYE SPECIALIST CENTRE**

**明亮眼科专科中心**

**TOPVISION EYE SPECIALIST BERHAD**

Registration No: 201801011816 (1273832-U)

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED  
INTERIM FINANCIAL STATEMENTS  
FOR THE THIRD QUARTER ENDED 30 SEPTEMBER 2024**

**TOPVISION EYE SPECIALIST BERHAD**  
**Registration No: 201801011816 (1273832-U)**  
**(Incorporated in Malaysia)**

**Unaudited Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income For the Third Quarter Ended 30 September 2024 <sup>(1)</sup>**

	Individual Quarter		Cumulative Quarter	
	30.9.2024 RM'000	30.9.2023 RM'000	30.9.2024 RM'000	30.9.2023 RM'000
Revenue	10,722	10,632	32,653	31,628
Cost of services	(5,448)	(5,576)	(16,110)	(16,063)
Gross profit	5,274	5,056	16,543	15,565
Other income	3	-	13	9
Administrative expenses	(3,682)	(3,086)	(10,356)	(9,104)
Finance costs	(218)	(205)	(701)	(584)
Finance income	14	24	48	79
Profit before tax	1,391	1,789	5,547	5,965
Tax expense	(567)	(641)	(1,883)	(1,862)
Profit after tax	824	1,148	3,664	4,103
Other comprehensive income	-	-	-	-
<b>Total comprehensive income</b>	<b>824</b>	<b>1,148</b>	<b>3,664</b>	<b>4,103</b>
Total comprehensive income for the financial year attributable to:-				
- Owners of the Company	759	1,125	3,502	4,013
- Non-controlling interest	65	23	162	90
	824	1,148	3,664	4,103
Basic/Diluted earning per share ("EPS") (sen) <sup>(2)(3)</sup>	0.30	0.44	1.37	1.57

**Notes:**

- (1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income are disclosed in Note A1 and should be read in conjunction with the Accountants' Report as disclosed in the prospectus of Topvision Eye Specialist Berhad ("Topvision" or the "Company") dated 25 November 2024 ("Prospectus") and the accompanying explanatory notes attached to this condensed consolidated interim financial report.
- (2) Basic earnings per share is calculated based on the Company's weighted average number of shares of 255,595,535 ordinary shares in Topvision ("Shares") as at the end of of the financial period.
- (3) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial quarter under review.

**TOPVISION EYE SPECIALIST BERHAD**  
**Registration No: 201801011816 (1273832-U)**  
**(Incorporated in Malaysia)**

**Unaudited Condensed Consolidated Statement of Financial Position As At 30 September 2024 <sup>(1)</sup>**

	Unaudited as at 30 September 2024 RM'000	Audited as at 31 December 2023 RM'000
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	46,160	34,905
Total non-current assets	<u>46,160</u>	<u>34,905</u>
<b>Current assets</b>		
Inventories	2,381	2,062
Trade receivables	944	1,410
Other receivables	3,561	1,952
Tax refundable	25	28
Cash and bank balances	6,432	6,573
Short-term investments	3,244	3,103
Fixed deposit with a licensed bank	210	210
Total current assets	<u>16,797</u>	<u>15,338</u>
<b>TOTAL ASSETS</b>	<u><u>62,957</u></u>	<u><u>50,243</u></u>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
<b>Equity attributable to the owners of the Company:-</b>		
Share capital	17,331	17,331
Retained earnings	19,281	15,714
Merger deficit	(3,641)	(3,641)
	<u>32,971</u>	<u>29,404</u>
Non-controlling interest	855	623
Total equity	<u>33,826</u>	<u>30,027</u>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
Lease liabilities	13,165	8,488
Borrowings	10,401	6,435
Deferred tax liabilities	5	5
Total non-current liabilities	<u>23,571</u>	<u>14,928</u>
<b>Current liabilities</b>		
Trade payables	752	665
Other payables	2,474	2,514
Lease liabilities	1,325	1,193
Borrowings	1,009	579
Tax payable	-	337
Total current liabilities	<u>5,560</u>	<u>5,288</u>
Total liabilities	<u>29,131</u>	<u>20,216</u>
<b>TOTAL EQUITY AND LIABILITIES</b>	<u><u>62,957</u></u>	<u><u>50,243</u></u>
Net assets per share (sen) <sup>(2)</sup>	13.23	11.75

**Notes:**

(1) The basis of preparation of the Unaudited Condensed Consolidated Statement of Financial Position are disclosed in Note A1 and should be read in conjunction with the Accountants' Report as disclosed in the Prospectus and the accompanying explanatory notes attached to this condensed consolidated interim financial report.

(2) Net assets per share is calculated based on the Company's number of ordinary shares at the end of the reporting period of 255,595,535 shares as at 30 September 2024 and 31 December 2023 respectively.

**TOPVISION EYE SPECIALIST BERHAD**  
**Registration No: 201801011816 (1273832-U)**  
**(Incorporated in Malaysia)**

**Unaudited Condensed Consolidated Statement of Changes in Equity As At 30 September 2024 <sup>(1)</sup>**

	Share Capital RM'000	Merger Deficit RM'000	Retained Earnings RM'000	Total RM'000	Non-controlling Interest RM'000	Total Equity RM'000
As at 1 January 2023	17,331	(3,641)	12,994	26,684	278	26,962
Total comprehensive income for the financial period	-	-	4,013	4,013	90	4,103
Transfer of shares to non-controlling interest of subsidiaries	-	-	45	45	240	285
Balance at 30 September 2023	17,331	(3,641)	17,052	30,742	608	31,350

	Share Capital RM'000	Merger Deficit RM'000	Retained Earnings RM'000	Total RM'000	Non-controlling Interest RM'000	Total Equity RM'000
As at 1 January 2024	17,331	(3,641)	15,714	29,404	623	30,027
Total comprehensive income for the financial period	-	-	3,502	3,502	162	3,664
Dividends	-	-	-	-	(45)	(45)
Transfer of shares to non-controlling interest of subsidiaries	-	-	65	65	115	180
Balance at 30 September 2024	17,331	(3,641)	19,281	32,971	855	33,826

**Note:**

(1) The basis of preparation of the Unaudited Condensed Consolidated Statements of Changes in Equity are disclosed in Note A1 and should be read in conjunction with the Accountants' Report as disclosed in the Prospectus and the accompanying explanatory notes attached to this condensed interim financial report.

**TOPVISION EYE SPECIALIST BERHAD**  
**Registration No: 201801011816 (1273832-U)**  
**(Incorporated in Malaysia)**

**Unaudited Condensed Consolidated Statement of Cash Flow <sup>(1)</sup>**

	30 September 2024 RM'000	30 September 2023 RM'000
<b>Cash flows from operating activities</b>		
Profit before tax	5,547	5,965
<b>Adjustments for:</b>		
Depreciation of property, plant and equipment	3,864	3,046
Interest expenses	701	584
Interest income	(48)	(79)
Operating profit before working capital changes	10,064	9,516
<b>Changes in working capital:-</b>		
Inventories	(319)	(696)
Receivables	(1,143)	(871)
Payables	47	(647)
Cash generated from operations	8,649	7,302
Tax paid	(2,218)	(2,153)
<b>Net cash generated from operating activities</b>	6,431	5,149
<b>Cash flows from investing activities</b>		
Interest received	48	79
Purchase of property, plant and equipment	(9,543)	(3,602)
Proceeds from transfer of shares of subsidiaries to non-controlling interest	180	285
<b>Net cash used in investing activities</b>	(9,315)	(3,238)
<b>Cash flows from financing activities</b>		
Dividend paid by a subsidiary to NCI	(45)	-
Drawdown of term loans	4,815	-
Interest paid	(701)	(584)
Repayments of term loans	(419)	(406)
Repayments of lease liabilities	(766)	(944)
<b>Net cash used in financing activities</b>	2,884	(1,934)
<b>CASH AND CASH EQUIVALENTS</b>		
Net changes	-	(23)
At beginning of the financial period	9,886	10,947
At end of the financial period	9,886	10,924

**Note:**

(1) The basis of preparation of the Unaudited Condensed Consolidated Statement of Cash Flow are disclosed in Note A1 and the accompanying explanatory notes attached to the interim financial report.

**TOPVISION EYE SPECIALIST BERHAD**  
**Registration No: 201801011816 (1273832-U)**  
**(Incorporated in Malaysia)**

**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE  
THIRD QUARTER ENDED 30 SEPTEMBER 2024**

**A. EXPLANATORY NOTES ON THE COMPLIANCE WITH MALAYSIA FINANCIAL REPORTING STANDARDS ("MFRS") 134**

**A1. Basis of Preparation**

The condensed consolidated interim financial report of the Topvision and its subsidiaries ("**the Group**") are unaudited and have been prepared in accordance with the Malaysian Financial Reporting Standards ("**MFRS**") 134: Interim Financial Reporting issued by the Malaysian Accounting Standards Board ("**MASB**") and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad ("**Bursa Securities**") ("**Listing Requirements**").

This condensed consolidated interim financial report should be read in conjunction with the Accountants' Report as disclosed in the Prospectus and the accompanying explanatory notes attached to this condensed consolidated interim financial report.

**A2. Changes In Accounting Policies**

The accounting policies and methods of computation adopted by the Group in this condensed consolidated interim financial report are consistent with those adopted in preparation of the Accountants' Report as disclosed in the Prospectus dated 25 November 2024 except for the adoption of the following amendments/improvements to MFRSs, which are applicable during the current financial year.

**Amendments to MFRSs effective for financial periods beginning on or after 1 January 2025**

Amendments to MFRS 121\*                      The effect of changes in foreign exchange rates: Lack of exchangeability

**Amendments to MFRSs effective for financial periods beginning on or after 1 January 2026**

Amendments to MFRS 1\*, 7,                      First- time adoption of Malaysia Financial Reporting Standards, financial instruments -  
9, 10 and 107                                      financial instruments, consolidated financial statements and statement of cash flows  
Amendments to MFRS 9 and 7                      Financial Instruments - Disclosures: Amendments to the Classification and Measurements of  
Financial Instruments

**MFRSs effective for financial periods beginning on or after 1 January 2027**

MFRS 18    Presentation and Disclosure in Financial Statements  
MFRS 19    Subsidiaries without Public Accountability - Disclosures

**Amendments to MFRSs - for a date yet to be confirmed**

MFRS 10 and 128                                      Consolidated Financial Statements and Investments in Associates and Joint Ventures:  
Sale or Contribution of Assets between an Investor and its Associates or Joint Venture

The initial application of the new and amended standards are not expected to have any material financial impacts to the condensed consolidated interim financial statements of the Group upon adoption.

\* Not applicable to the Group's operations.

**TOPVISION EYE SPECIALIST BERHAD**  
**Registration No: 201801011816 (1273832-U)**  
**(Incorporated in Malaysia)**

**A3. Auditors' Report On Preceding Annual Financial Statements**

There was no qualification on the audited financial statements of the Group for the financial year ended 31 December 2023.

**A4. Seasonal or Cyclical Factors**

The Group's operations were not affected materially by seasonal or cyclical factors for the current financial quarter under review.

**A5. Material Unusual Items**

There were no material unusual items affecting assets, liabilities, equity, net income or cash flows of the Group during the current financial quarter under review.

**A6. Material Changes in Estimates**

There were no material changes in accounting estimates in the current financial quarter under review.

**A7. Debt and Equity Securities**

There were no other issuance, cancellation, repurchase, resale and repayment of debt and equity securities in the current financial quarter under review.

**A8. Dividend Paid**

There was no dividend paid during the current financial quarter under review.

**A9. Segmental Information**

There were no products, services and geographical location segment information are presented as the Group is viewed as a single reportable segment.

**A10. Material Events Subsequent To The End Of The Quarter**

Save as disclosed in Note B6 on the Status of Corporate Proposals, there were no other material events subsequent to the end of the current financial quarter under review that have not been reflected in this condensed consolidated interim financial report.

**A11. Changes In The Composition Of The Group**

The changes in the composition of the Group during the current financial quarter are as follows:-

- (i) The Company had disposed off 30,000 shares in Topvision Eye Specialist Centre (Seremban) Sdn Bhd ("TVESB") representing 1.5% of the total paid-up capital of TVESB to TVESB's resident doctor at RM30,000 pursuant to the Share Option Agreement dated 5 July 2021.
- (ii) The Company had disposed off 30,000 shares in Topvision Eye Specialist Centre (Taiping) Sdn Bhd ("TVETP") representing 1.5% of the total paid-up capital of TVETP to TVETP's resident doctor at RM30,000 pursuant to the Share Option Agreement dated 1 July 2022.
- (iii) The Company had disposed off 15,000 shares in Topvision Eye Specialist Centre (Kota Bharu) Sdn Bhd ("TVEKB") representing 0.75% of the total paid-up capital of TVEKB to TVEKB's resident doctor at RM15,000 pursuant to the Share Option Agreement dated 1 January 2023.
- (iv) The Company had disposed off 30,000 shares in Topvision Eye Specialist Centre (Sungai Petani) Sdn Bhd ("TVESP") representing 1.5% of the total paid-up capital of TVESP to TVESP's resident doctor at RM30,000 pursuant to the Share Option Agreement dated 1 July 2023.
- (v) The Company had acquired additional 200,000 shares in Topvision Eye Specialist Centre (Kuala Terengganu) Sdn Bhd ("TVEKT") at RM1 each for cash consideration of RM200,000, which did not result in changes in effective equity interest.

**TOPVISION EYE SPECIALIST BERHAD**  
**Registration No: 201801011816 (1273832-U)**  
**(Incorporated in Malaysia)**

**A12. Contingent Assets And Contingent Liabilities**

There were no contingent assets and contingent liabilities as at the date of this condensed consolidated interim financial report.

**A13. Capital Commitments**

	<b>30.9.2024</b>	<b>30.9.2023</b>
	<b>RM'000</b>	<b>RM'000</b>
Contracted but not provided for	6,962	9,791
Approved but not contracted for	-	-
	6,962	9,791

**A14. Significant Related Party Transactions**

	<b>Individual Quarter</b>		<b>Cumulative Quarter</b>	
	<b>30.9.2024</b>	<b>30.9.2023</b>	<b>30.9.2024</b>	<b>30.9.2023</b>
	<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>	<b>RM'000</b>
Consultancy fees charged by a Company in which a person connected to a Director has interests	510	604	1,703	1,812
Rental expenses charged by a Director	16	16	48	48
Rental expenses charged by a person connected to a Director	41	36	124	108
Rental expenses charged by a Director and a person connected to a Director	12	-	36	-
	12	-	36	-



**TOPVISION EYE SPECIALIST BERHAD**  
**Registration No: 201801011816 (1273832-U)**  
**(Incorporated in Malaysia)**

**B. EXPLANATORY NOTES PURSUANT TO PART A OF APPENDIX 9B OF THE LISTING REQUIREMENTS**

**B1. Review Of Performance**

**Individual Quarter Ended 30 September 2024 against 30 September 2023**

The Group recorded a revenue of RM10.72 million for the current financial quarter under review, as compared to RM10.63 million in the corresponding financial quarter. This represents an increase of RM0.09 million or 0.85%.

The increase in revenue is mainly due to the business commencement of our newly established centres - Mentakab which commenced its operation in August 2024.

Despite the slight increase in revenue, the Group's profit before tax ("PBT") showed a decreased of RM0.40 million or 22.25% comparing to previous quarter. This is mainly due to our Kota Bharu, Sungai Petani and Mentakab centre which is still in its early stages of operations recorded loss as compared to other more established centres, thus lowering the Group's overall PBT. Beside that, those newly established centres - Kuala Terengganu, Tawau and Topvision International which is at its preliminary stage of setting up costs also lowered down the overall Group's PBT.

**Cumulative Quarter Ended 30 September 2024 against 30 September 2023**

The Group recorded a revenue of RM32.65 million for the current financial period under review, as compared to RM31.63 million in the corresponding financial period. This represents an increase of RM1.02 million or 3.22%. The increase was primarily due to:

- (i) an increase in revenue generated by our Sungai Petani centre. This centre only recorded 4 months revenue in the corresponding financial period as it only commenced its operation in June 2023;
- (ii) an increase in revenue generated by our Mentakab centre as it commenced its operation in August 2024; and
- (iii) the organic growth of revenue by some of our existing centres during the current financial period as compared to the corresponding financial period.

Despite the increase in revenue, the Group's PBT showed a decrease of RM0.41 million or 6.88% due to the following reasons:

- (i) an increase in staff costs due to increased headcount during the financial period whereby there was an increase in number of optometrists, staff nurses, healthcare assistants and executives, which was in line with the expansion of operations following commencement of our Mentakab centre's operations;
- (ii) an increase in depreciation costs arising from depreciation of our property, plant and equipment after purchasing property, plant and equipment for our Mentakab centre; and
- (iii) pre-operation costs were incurred for the establishment of Kuala Terengganu and Tawau centre.

**B2. Comparison With Immediate Preceding Quarter**

	Immediate Preceding		Changes %
	Current quarter 30.9.2024 RM'000	Quarter 30.6.2024 RM'000	
Revenue	10,722	11,910 -	9.99
Profit before tax	1,391	2,557 -	45.60

For the current financial quarter, the Group recorded revenue of RM10.72 million, a decrease of 9.99% or RM1.19 million from RM11.91 million in the immediate preceding quarter. The decrease in revenue can primarily attributable to during the current financial quarter, whereby a few of our centres' resident doctor went for conference in overseas for few weeks which caused lesser surgery being done during this quarter.

The Group's PBT decreased by RM1.17 million mainly due to the decrease in revenue in the current financial quarter under review coupled with an increase in administrative expenses (ie. increase in depreciation costs for our Mentakab centre which commenced operation in August 2024)

**TOPVISION EYE SPECIALIST BERHAD**  
**Registration No: 201801011816 (1273832-U)**  
**(Incorporated in Malaysia)**

**B3. Prospects Of The Group**

The Group remains committed to continuously put in place the following future plans and strategies to leverage on our existing capabilities and competencies to become one of the medical eye care group in the country:

- (i) expansion of the Group's network by establishing Topvision International Eye Specialist Centre ("TIESC") by year 2025, and 1 new ambulatory care centre in the East Coast Region of Malaysia; and
- (ii) expansion of the Group's range of services include refractive suite, offering refractive surgeries for customers wanting spectacle independence such as Laser-Assisted In Situ Keratomileusis ("LASIK") and Implantable Collamer Lens procedure as well as aesthetic double eyelid surgical procedure as an added offering by year 2025 with the establishment of TIESC.

Looking ahead, barring any unforeseen circumstances, the Board of Directors of the Company ("**Board**") is of the opinion that the prospects of the Group's performance for the financial year ending 31 December 2024 will still remain favourable.

**B4. Profit Forecasts**

The Group has not issued any profit forecast or profit guarantee in any form of public documentation and announcement.

**B5. Tax Expense**

	Individual quarter		Cumulative quarter	
	30.9.2024 RM'000	30.9.2023 RM'000	30.9.2024 RM'000	30.9.2023 RM'000
Current taxation	567	641	1,883	1,862
Effective tax rate (%)	40.76%	35.83%	33.95%	31.21%

The overall effective tax rate for the current individual and cumulative financial quarter ended 30 September 2024 was higher than the statutory tax rate of 24.00%, mainly due to expenses that was not deductible for tax purposes, such as depreciation of non-qualifying property, plant and equipment and non-allowable expenses for pre-commencement of operation expenses.

Income tax expense in the form of provision is recognised based on management's estimation.

**B6. STATUS OF CORPORATE PROPOSAL**

On 25 November 2024, the Company issued its Prospectus in relation to the public offering of 54,220,000 ordinary shares ("**Shares**") in Topvision in conjunction with the transfer of listing of the Company from the LEAP Market to the ACE Market of Bursa Securities ("**Transfer of Listing**") comprising the following:

- (i) 33,928,000 new Shares to the institutional and selected investors;
- (ii) 15,492,000 new Shares available for application by the Malaysian public; and
- (iii) 4,800,000 new Shares available for the Company's eligible directors, eligible employees and persons who have contributed to the success of the Group.

**TOPVISION EYE SPECIALIST BERHAD**  
**Registration No: 201801011816 (1273832-U)**  
**(Incorporated in Malaysia)**

**B6. STATUS OF CORPORATE PROPOSAL (CONT'D)**

The Transfer of Listing Bursa Securities comprises the following:

- (i) the admission to the Official List and the listing of and quotation for the Company's entire enlarged issued share capital of 309,815,535 Shares on the ACE Market of Bursa Securities pursuant to Rules 3A.02(1) and 3A.02(2) of the Listing Requirements ("**Listing**"); and
- (ii) the voluntary withdrawal of listing of the Company from the LEAP Market of Bursa Securities pursuant to Rules 8.05 and 8.06 of the LEAP Market Listing Requirements of Bursa Securities ("**Withdrawal**").

The Transfer is pending completion as the Company is expected to be transferred to the ACE Market of Bursa Securities on 16 December 2024.

Save as disclosed above, there were no corporate proposals announced but pending completion as at the date of this report.

**B7. UTILISATION OF PROCEEDS FROM THE IPO**

The gross proceeds from the IPO amounting to RM17.893 million is expected to be utilised in the following manner:

Purpose	Proposed utilisation	Actual Utilisation	Balance	Estimated timeframe for utilisation upon listing
	RM'000	RM'000	RM'000	
Establishment of Topvision International	7,900	-	7,900	Within 18 months
Establishment of:	5,000	-	5,000	Within 24 months
- Topvision Kuala Terengganu				
- Topvision Tawau				
Purchase of machines	498		498	Within 12 months
Estimated expenses for Transfer of Listing	4,495	-	4,495	Within 1 months
<b>Total</b>	<b>17,893</b>	<b>-</b>	<b>17,893</b>	

The utilisation of the proceeds as disclosed above should be read in conjunction with the Prospectus of the Company. As at the date of this condensed consolidated interim financial report, the IPO is pending completion, hence there are no utilisation of proceeds by the Group yet.

**B8. GROUP LOANS AND BORROWINGS**

The details of the Group's loans and borrowings are as follows:

	Unaudited as at 30 September 2024 RM'000	Audited as at 31 December 2023 RM'000
<b>Non-current</b>		
Term loans	10,401	6,435
Lease liabilities	13,165	8,488
	23,566	14,923
<b>Current</b>		
Term loans	1,009	579
Lease liabilities	1,325	1,193
	2,334	1,772
	25,900	16,695

All the Group's borrowings are secured and denominated in Ringgit Malaysia.

**B9. MATERIAL LITIGATIONS**

The Board is not aware of any material litigations pending or threatened against the Group as at the date of this report.

**B10. DIVIDENDS**

There were no dividend proposed by the Board for the current financial period.

**TOPVISION EYE SPECIALIST BERHAD**  
**Registration No: 201801011816 (1273832-U)**  
**(Incorporated in Malaysia)**

**B11. BASIC/DILUTED EARNINGS PER SHARE**

The basic and diluted EPS for the current quarter are computed as follows:

	Individual quarter		Cumulative quarter	
	30.9.2024	30.9.2023	30.9.2024	30.9.2023
	RM'000	RM'000	RM'000	RM'000
Profit attributable to owners of the Company	759	1,125	3,502	4,013
Number of ordinary shares ('000)	255,595	255,595	255,595	255,595
Basic/Diluted EPS (sen) <sup>(1)(2)</sup>	0.30	0.44	1.37	1.57

**Note:**

1. Basic and diluted EPS is calculated based on the Company's weighted average number of shares of 255,595,535 ordinary shares as at the end of the financial period.
2. Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial quarter under review.

**B12. PROFIT BEFORE TAX**

Profit before tax is arrived after charging/(crediting):

	Individual quarter		Cumulative quarter	
	30.9.2024	30.9.2023	30.9.2024	30.9.2023
	RM'000	RM'000	RM'000	RM'000
<b>Material expenses/(income)</b>				
Depreciation of property, plant and equipment	1,647	1,137	3,864	3,046
Finance income	(14)	(24)	(48)	(79)
Finance costs				
- term loans	42	45	127	133
- lease liabilities	176	160	574	451
<b>Expenses arising from leases</b>				
Expenses relating to short-term leases	57	52	172	156